CPT code 11981 covers the insertion of a bioresorbable, biodegradable, or non‑biodegradable implant (such as a capsule or pellet) that contains a drug for long‑term delivery. This code defines a procedural category increasingly relevant as sustained‑release implants expand across specialties including oncology, pain management, ophthalmology, and endocrinology. Nationally, accurate coding for device‑based drug delivery affects claims processing, device tracking, and longitudinal therapy management.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, common sites of service, and how the code is used in practice. The publication summarizes payer coverage patterns and benchmarks where available, highlights relevant policy updates affecting reimbursement and prior authorization, and outlines common billing considerations tied to this procedure type.

The report provides practical reference material for billing and compliance teams, including typical care settings, the clinical rationale for long‑term implants, and points of attention for claims submission. Data not available in the input is identified explicitly where applicable.